key: cord-0809987-j4y1fgxm
authors: Bhavana, Valamla; Thakor, Pradip; Singh, Shashi Bala; Mehra, Neelesh Kumar
title: COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic
date: 2020-08-23
journal: Life Sci
DOI: 10.1016/j.lfs.2020.118336
sha: 5bd87b6d2f5aa30b11f13293187c1250cc39bb4d
doc_id: 809987
cord_uid: j4y1fgxm

The recent corona virus disease (COVID-19) outbreak has claimed the lives of many around the world and highlighted an urgent need for experimental strategies to prevent, treat and eradicate the virus. COVID-19, an infectious disease caused by a novel corona virus and no approved specific treatment is available yet. A vast number of promising antiviral treatments involving nanotechnology are currently under investigation to aid in the development of COVID-19 drug delivery. The prospective treatment options integrating the ever-expanding field of nanotechnology have been compiled, with the objective to show that these can be potentially developed for COVID-19 treatment. This review summarized the current state of knowledge, research priorities regarding the pandemic and post COVID-19. We also focus on the possible nanotechnology approaches that have proven to be successful against other viruses and the research agenda to combat COVID-19.

Because R0represents an average value it is also important to consider the role of super spreaders, who may be hugely responsible for outbreaks within large clusters but who would not largely influence the value of R0 [26] .R0 remains unstable during the initial stages of pandemic due to short onset time and insufficient data availability.

Prevention is always better than cure to combat of any infectious disease. To fight the unprecedent and rapidly progressing COVID-19, the only solution is to follow preventive measures. Washing hands frequently with water and soap, or clean them with alcohol-based sanitizers, maintaining at least 1meter distance, covering mouth-nose during coughing or sneezing. Practice physical distancing devoid unnecessary travel and staying away from large groups of peoples [27] . For early detection of the virus, public awareness should be created regarding the unusual symptoms like chronic cough or shortness of breath. Quarantine of suspected people, isolation of the infected people and their close contacts can be the crucial step in eradication of the virus.

Mitigating social gatherings, temporary school closure, home isolation, close monitoring of symptomatic individual, provision of life supports (e.g. oxygen supply, mechanical ventilator), personal hand hygiene, and wearing personal protective equipment such as facemask should also been forced by the government to prevent the further transmission of virus [28] .

angiotensin-converting enzyme-2 (ACE-2) or CD-147or dipeptidyl peptidase 4 (DPP-4) [29] or transmembrane protease serine 2(TMPRSS2) and the second is cleavage of the spike protein by the TMPRSS2 [30] , which exposes the fusion peptide, allowing it to survive in low-pH endosomes [31] .

ACE-2 receptors have been found as the main cellular receptor for binding with the receptor-binding domain of virus spikes and responsible receptors for human-to-human transmissions of SARS-CoV. ACE-2 protein is abundantly found in alveolar epithelial cells of lungs and enterocytes of small intestine. It was found that the virus primary binds to the target site on lung epithelial cells. Wang et al also found that ACE-2 was abundantly expressed in gallbladder, liver, kidney, testes, gastrointestinal tract, and bladder suggesting that these organs may be vulnerable to SARS-CoV-2 infection, which may help to understand the routes of infection and disease manifestations [32] . However, patients with SARS-CoV-2 infection primarily exhibit lesions in the lungs, despite the ACE-2 receptor being widely distributed in various organs of the human body, so this connection needs to be investigated further.

In addition, ACE-2 is highly expressed in vascular endothelial cells, which raises the question of whether the virus can cause damage to vascular endothelial cells or impact glomerular function. Xu et al. recently found that it has been seen rare kidney damage in COVID-19 patients in Zhejiang [33] . It is not clear yet that the SARS-CoV-2binds with ACE-receptors only or other receptors also. The organs withACE-2positive cells match the organs involved with the disease, as reported in clinical studies, which raises the question of whether novel coronavirus infection causes more deaths by multiple organ dysfunction syndrome (MODS) or respiratory failure [31] .

SARS-CoV-2 spike (S) glycoprotein binds with ACE-2 receptor and it is a crucial step for the virus entry in to host cells. Homotrimers (S1 and S2) of S proteins assists the attachment to the host receptors. The S2 subunit of SARS-Cov-2 is highly conserved and serves as a target for antiviral therapeutics. Several therapeutics approaches of virusreceptor binding affinity are under investigation. Systematic detection of β-CoV receptors showed that human cells expressing ACE-2 was enhanced the detection of entry of SARS-CoV-2 but human Dipeptidyl peptidase-4 (DPP4) or APN (Aminopeptidase N) had not enhanced entry of SARS-CoV-2. While, another study showed that S protein of SARS-CoV2 and ACE-2 binding efficiency is 10-to 20-fold higher than that of SARS-CoV. It is evidenced by Cryo-TEM Structure of the SARS-CoV-2 Spike in the prefusion conformation [34] . (TNF-α), IL-1β, IL-8,   IL-12, monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1A (MIP1A)and interferon-gamma inducible protein (IP10) are also increased in SARS CoV-2 infected patients as shown in figure 2 [30] . The incidence of ARDS, shock, secondary infection, acute kidney injury and heart was significantly higher in patients with intensive care unit (ICU) than in non-ICU patients. The main proportion of IL-6 above normal was significantly higher than that in the patients. Infection with MERS coronavirus can induce increased concentration of pro-inflammatory cytokines (tumor 616 necrosis factor α, IL15, and IL17, and interferon-γ,). The severe COVID-19 cases may benefit from IL-6 pathway inhibition given the associated Cytokine Release Syndrome (CRS) and sHLH (Secondary hemophagocytic lymphohistiocytosis) like serum cytokine elevations, which may be a target of the treatment of COVID-19 infected patients [35] . Excessive tissue damage is occurred owing to the excessive release of cytokines. In some cases, a reaction takes place which is labeled as 'cytokine storm'. This is given in figure 3 with its possible treatments [36] . It is able to promote the differentiation of B lymphocytes, promotes the growth of some categories of cells, and inhibits the growth of others [30] .CD4 + T/CD8 + T counts continued to decline until death. Wan et al. found that CD4 + T and CD8 + T were lower in severe patients, which suggested that lymphocytes were more inhibited in severe patients.

Lymphocytopenia may be related to a cytokine storm caused by viral invasion. In mild patient, reduction rate of CD4 + T, CD8 + T, B cell are less as compared to severe patients [37] .

Avoidance is the principal method of deterrence. Searching of accurate treatment for COVID-19 patients has been in progress and wide range of possible treatments is being tested by researchers. Numerous collaborative efforts to discover and evaluate the effectiveness of anti-viral, immune-therapies, monoclonal antibodies, and vaccines have rapidly emerged. These all treatment is symptomatic but oxygen therapy using ventilator plays major role in the treatment of COVID-19. All the recommended treatments for COVID-19 as shown in figure 4.

When respiratory failure is occurred in COVID-19 patients, mechanical ventilation becomes the necessary treatment. In addition, hemodynamic support is also required for managing septic shock. Mechanical ventilation should be with lower tidal volumes (4 to 6 J o u r n a l P r e -p r o o f Journal Pre-proof ml/kg predicted body weight; PBW) and lower inspiratory pressures, reaching a plateau pressure (Pplat) < 28 to 30 cm H 2 O[38]. Positive end-expiratory pressure (PEEP) must be as high as possible to maintain the driving pressure (Pplat-PEEP) and as low as possible (< 14 cmH2O). Moreover, one must always remember that avoiding disconnections from the ventilator for preventing loss of PEEP and atelectasis. Finally, the use of paralytics is not recommended unless PaO2/FiO2 (partial oxygen pressure/fraction of inspired oxygen)< 150 mmHg. The prone ventilation for > 12 hours per day, and the use of a conservative fluid management strategy for ARDS patients without tissue hypo perfusion (strong recommendation) are emphasized [30] .

As previously discussed, no effective drug treatment is available for fighting this COVID-19. But several drugs including anti-viral, anti-malarial, anti-microbial and several anti-bacterial drugs have been available and using in the treatment against COVID-19.

Mostly combination of drugs serves as an effective treatment against COVID-19. Systemic corticosteroids (Hydrocortisone, methyl prednisolone, dexamethasone, and prednisolone) are not recommended in the treatment of viral pneumonia or ARDS due to the increased mortality and secondary infection rates in influenza, impaired clearance of SARS-CoV and MERS-CoV, and complications of corticosteroid therapy in survivors [39] .

Moreover, COVID-19 is a viral disease not bacterial infection. Therefore, one should avoid in-appropriate administration of antibiotics, although some treatment centre recommended it. Several approaches have been proposed such as lopinavir/ritonavir (400/100 mg every 12 hours), chloroquine (500 mg every 12 hours), and hydroxylchloroquine (200 mg every 12 hours). Alpha-interferon (e.g., 5 million units by aerosol inhalation twice per day) is also used [30] . reported that patients received remdesivir had a 31% times faster recovery in comparison to placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared to 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0% for the group receiving remdesivir versus 11.6% for the placebo group (p=0.059) [30] .

Although several studies have been available suggesting remdesivir give no proper results against COVID-19. Wang et al carried out randomised, double-blind, placebocontrolled, multicentre trial of remdesivir on 237 COVID-19 patients. The 158 patients were given Remdesivir out of 237 patients, and 79 patients were given placebo formulation.

It was found that clinical improvement in the remdesivir group was not significantly different to that of the control group. Remdesivir had a numerically faster time to clinical improvement in comparison to placebo. Mortality rate of both the groups was similar [40] . Arbidol. Total 240 patients were taken. Among them, 120 patients were given treatments of favipiravir and 120 patients were given the treatments of Arbidol. It was found that no difference was seen in both treatments after 7 days. Favipiravir showed significant relief in cough and pyrexia after 7 days treatments [43] .

Clinical trials in the initial stages failed and no difference was observed in COVID-19patients. In addition to remdesivir, we tend to evaluate all of the evidence related to the other antiviral drugs, which called the attention, such as ribavirin, favipiravir, oseltamivir and umifenovir [44] . Ribavirin (Tribavirin) is a broad-spectrum guanosine analogue against RNA and DNA viruses such as hepatitis C and E [45] . Ribavirin in conjunction with interferon showed synergistic activity in in vitro antiviral study. This result suggested that ribavirin elicits antiviral activity at lower concentration with interferon. Therefore, a combination therapy of interferon and ribavirin were widely used due to synergistic effect. Simultaneous use of three or more antiviral drugs is not recommended and patient J o u r n a l P r e -p r o o f symptoms will recover after drug withdrawal. Antiviral drugs should be stopped if nucleic acid test results from sputum specimens remain negative for more than three times [46] .

Chloroquine and hydroxychloroquine (HC) had received intense attention because of viral enzymes or processes inhibition especially in Iran, U.K, France. However, FDA revoked the emergency use authorization due to severe cardiac adverse events and other potential side effects. The potential benefits of chloroquine and HC no longer outweigh the potential risks for the authorized use [47] . HC is superior to chloroquine and reported positive results in some pre-clinical data in vitro and protocols. Both of these anti-malaria drugs might actually do more harm than good due to many side effects and should be prescribed not more than 7 days. The main concerns in rare cases are cardiac arrest, retinal damage and ocular toxicity, particularly due to the fact that, people with heart conditions are at higher risk of severity [48] . Magagnoli et al. conducted study to study the outcomes of hydroxychloroquine in COVID-19 patients. This study was carried out on total 368 patients and it was divided in three groups namely HC treatments, without HC treatments and combination treatments of HC and azithromycin. Primary outcome of this study was analysis of mortality rate and required ventilation facility on these groups. It was found that 27.8, 22.1 and 11.4 mortality rate was found in HC group, combination group and without HC group, respectively. It was also found that mechanical ventilation occurred in 13.3% of the HC group, 6.9% of the combination group, and 14.1% of the without HC group. Therefore, it was investigated that no effect was found in mortality rate after HC treatment and combination treatments but, significant reduction of mechanical ventilation was observed after combinational treatments when compared to other two groups [50] . The management of venous thromboembolism (VTE) and antithrombotic therapy for acute coronary syndromes (ACS) is very crucial in covid-19 pandemic. Anticoagulants like Vitamin K antagonists, dabigatran, apixaban, betrixaban, edoxaban, rivaroxaban and antiplatelets like clopidogrel, prasugrel ticagrelor, cilostazol may have interactions with COVID -19 investigational drug. Therefore, drug interactions should be kept in mind to mitigate the thrombotic and hemorrhagic events in high-risk patients [52] .

Various monoclonal antibody has been explored in the treatment of COVID-19.

Mainly, gimsilumab and leronlimab have been used in the treatment of COVID-19.

Gimsilumab targets a pro-inflammatory cytokine known as a granulocyte-macrophage colony-stimulating factor (GM-CSF). The expression of pro-inflammatory cytokines was inhibited by gimsilumab, which increases inflammation. By this mechanism, it reduces the cytokine storm in the airway pathways and provides symptomatic relief to patients from COVID-19 [53] . In a recent study, it was identified that monoclonal antibody namelyCR3022 binds and cover the spike RBD of virus. Therefore, ACE-2 receptor cannot bind with the epitopes of monoclonal antibody, which cover the RBD of virus.

Although entry of virus into body, it cannot be replicated due to unavailability of binding site of host virus [41] . CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection. Leronlimab CCR5 is a protein on the surface of white blood cells that plays an important role in the way HIV develops in the human body.

Leronlimab is a monoclonal antibody being studied as a potential treatment for HIV. It binds to the CCR5 receptor, which inhibits the release of inflammatory cytokine [54] .

Convalescent plasma (CP) is a promising plasma antibody treatment that could help patients whose bodies cannot produce enough antibodies fighting against COVID-19 to cure the disease. With support from UK National Institute for Health Research (NIHR), the trial is led with NHS Blood and Transplant and University of Cambridge experts [55] .

The UK Government approved a national clinical trial to assess plasma therapy for the J o u r n a l P r e -p r o o f treatment of COVID-19 patients. This trial will decide that these treatments should be used or not in the COVID-19 patients in future. If the treatment will become effective, total 10,000 units of convalescent plasma will be supplied to the patients in a scaled-up national programme that enabling the treatment of 5,000 patients per week [55] . Duan et al. checked the effectiveness of convalescent plasma therapy for COVID-19 patients. It was observed that anti-bodies levels were sudden increased and reduced the concentration of reactive proteins in COVID-19 patients. The clinical symptoms were significantly improved along with increase of oxy-hemoglobin saturation within 3 days without any adverse effects [56] .

Researchers will use plasma from patients recovering for at least 28 days to increase antibody levels. The main findings from available data are as follows: (a)mortality may be reduced by plasma therapy in critically ill patients, (b) neutralizing antibody titers are increased and disappearance of SARS-CoV-2 RNA after CP therapy, and (c) beneficial effect on clinical symptoms after administration of convalescent plasma [57] .

Plasma therapy in COVID-19 patients shown safe, clinically effective, and reduces mortality based on the limited scientific data. In this simple method, doctors isolate antibodies from the plasma of recovered patients blood and administer them to currently exposed and infected patients. Antibodies aids in the recognition of the pathogens and reject the pathogen in the patients [55] . However, large multicenter clinical trials are urgently needed to conclude the optimal doses and treatment time point for the CP therapy to tackle COVID-19 pandemic.

Currently, COVID-19 has non-specific treatment. In humans, COVID-19 kicks off the respiratory system through droplets from coughs and sneezes of infected persons. Generally, respiratory system can be divided into two regions namely upper (nasal cavity, sinuses, nasopharynx, oropharynx, larynx, and trachea) and lower tract (bronchioles, alveolar ducts and alveolar sacs).Their journey to the lower respiratory tract after infecting the upper respiratory tract is the cause of respiratory illness [58] .

Major obstacles in drug delivery to upper respiratory tract are smaller surface area, lower blood flow, mucus layer (traps inhaled substances) and filtration of foreign objects [59] . The large surface area, ciliated cells of lower respiratory tract may be ideal area for delivery as it is connected directly to systemic circulation via pulmonary circulation with few challenges like branched nature alveolar macrophages and pulmonary surfactant J o u r n a l P r e -p r o o f Journal Pre-proof (phospholipids, proteins and mucins) decrease delivery efficiencies [60] . However, the delivery to lower tract should overcome muco-ciliary and cough clearance mechanisms. To address these barriers nanotechnology-based approaches can be implemented due to their characteristic features.

Studies reported that the microparticles (MPs) with aerodynamic size between 1-5 μm could escape the mucociliary clearance and deposit in the lower airways. This aerodynamic size range is mainly using in several commercial inhalation products [61] . Ribavirin, Zanamivir, Laninamivir, Interferon-α2 are currently available inhaled anti-viral agents against the human respiratory viruses RSV, rhinovirus, influenza A and B, parainfluenza, adenovirus and coronavirus [62] .

Nanotechnology is defined as the application of particles with dimension(s) of roughly 1 to 100 nanometer scale by the National Nanotechnology Initiative [63] . The principal mechanisms of particle deposition in the respiratory tract depend on particle size; for larger particles, impaction and sedimentation are important, but for nanoparticles less than 160 nm in diameter, diffusion represents the principal mechanism. Hence, nanoparticles and micro-particles approaches provides a broad range of opportunities for COVID-19 with new solutions for clinical problems [64] .

Nanotechnology has immense potential to aid in the development of COVID-19 drug delivery due to wide range of advantages such as (i) the small size and morphology of the nanoparticles (NP) enables the drug delivery to physiologically in-accessible sites and eliminate immune response by reticular endothelial cells [64] , (ii) large surface-to-volume ratio of NP increases drug loading [65] , (iii) the ability to cross negatively charges membranes due to surface charge modification of NP [66] , and (iv) NP possess intrinsic virucidal activity, such as gold and silver NP [67] .

The performance of the COVID-19 therapeutics can be ameliorated by various approaches of particulate drug delivery systems such as (i) encapsulation of therapeutics in the core to increase stability (ii) specific targeting through targeting moieties (iii) functionalization with polymer like PEG to decrease the amount of drug required to produce action. Metallic, organic, and hybrid NP as well numerous nanocarriers are different approaches of nanotechnology in conjunction with large porous micro-particles (LPMP), solid lipid micro-particles (SLMs) can be used for anti-viral therapy [64] .

LPMP represent an outstanding approach to improve deep lung deposition and to bypass macrophage uptake. LPMP are light particles, with an appropriate aerodynamic J o u r n a l P r e -p r o o f Journal Pre-proof diameter of 1-3 μm, large geometric diameter of 5-30 μm and density of < 0.4 g/cm3. The high porosity of LPMP allows them to penetrate deeply into lungs by inhalation. However, particles of 1-5 μm tend to aggregate via van der Waals attraction and 1-3 μm particles are captured by lung macrophages thus reducing their effect. Therefore, longer residence time was observed with MP of geometric diameter ≥ 20 μm being too large to be phagocytosed by alveolar macrophages. Therefore, particles should be light with large geometric diameter and low aerodynamic diameter to achieve deep delivery into lungs [68] . Garcia-Contreras et al.

formulated large porous particles for treatments of tuberculosis in guinea-pig model [69] .

Like COVID-19, in tuberculosis disease also requires to reach the drug at lung site. It was observed that treatments of lung infection using large porous particle significantly reduced bacterial burden as compared to other drug delivery.

Ben-jebria et al. formulated pulmonary aerosol drug delivery for porous microparticles. It was found that particles deposit inside the lower lungs was increased as compared to conventional dosage form. The systemic bioavailability by pulmonary route was increased using porous microparticles [70] . It was also observed that drug release from the formulation was sustained, which is required in COVID-19 patients. release formulation was prepared and it was evaluated using in vitro method [73] . Hence, SLM would become effective delivery in COVID-19 infection.

Inorganic nanoparticles (INPs) are utilized for a wide variety of purposes such as targeted imaging for diagnostics, photothermal therapy, medication and many promising applications in the biomedical field [74] . Metallic NP (MNP) and nanocarriers (NC) can be categorized under inorganic NP. Smaller particle size, controlled tunability, improved stability, enhanced permeability, large surface-to volume ratio are the characteristic features of inorganic NP [75] . Metallic NP such as silver, gold, iron oxide and nanocarriers of silica, titanium, carbon are the most common inorganic -NP. Silver nanoparticles (AgNP) are widely researched nanotechnology approach to treat viral infections. Many assumptions of NP have already been made to develop a novel strategy to eliminate or improve the severity of the infection.

Anti-viral activity of AgNP is well established in treating viruses such as HIV, HBV, HSV, RSV [74] . The virucidal activity of AgNP may not be similar in all viruses. For example, the viral inhibition in HSV-2 is achieved due to binding of AgNP to sulfhydryl group of surface glycoproteins of virus which prevent viral internalization. In virus like Peste des petits ruminants, AgNP interacts with virion surface and core protein to impair viral entry into target cells [76] . The virucidal activity of AgNP by these modes can be explored to improve the activity of therapeutics. In recent literature survey, Oron Zachar concluded that colloidal silver of particle sizes between 3nm-7nm can be highly effective to prevent and treat viral infection at initial stage of respiratory infections [77] . Sarkar has hypothesized that the application of water dispersed AgNP (10 nm) in conjunction with bronchodilators in lungs through simple nebulizer machine or bi-level ventilation may result in better virucidal activity [78] . Therefore, the anti-viral efficiencies of MNP for the treatment of COVID-19can be explored with particular emphasis on formulation composition, delivery method and safety for clinical evaluation. that fullerene-coated surfaces with size less than 60 nm can be used to decrease the adhesion of virus on the surface, as they will be hydrophobic as well as toxic to the envelope and prevent transmission [85] . In this regard, fullerenes can be considered as attractive spherical frameworks for a multivalent presentation of ligands.

Carbon nanotubes (CNT) are unique, 3D carbon-based nanoparticles, composed of thin graphite tubular sheets rolled up into hollow and tiny nano-needle tubular structure used in the field of biological sciences in last few decades [86] . CNTs belong to the fullerene family. They have small size dimensions (10-100 nm), high dimensionality (2D, and 3D),excellent electrical, thermal and mechanical properties and physicochemical features like surface load capacity and great storage space in the inner tube (inner void space) will result in biological properties, such as good biocompatibility, bio-absorption rate, permeability of biological barriers, multi-energy surface/tube chemical functional group capability, and targeted bio-molecules modification potency, etc [87] . Currently, the applications of CNTs in the biomedical field are explored by surface functionalization, grafting targeted molecules on the surface for site specific delivery, exploiting it superior near-infrared light absorption characteristics and good photothermal conversion [88, 89] . Yang proposed project to J o u r n a l P r e -p r o o f illuminate new way to fight COVID-19 with acidizing and RNA lyase-modified CNTs in conjunction with photodynamic thermal effect. Authors explored the nature of CoV, as they are labile to acidic environment and high temperature [90] . These characteristics provide new ideas for the development of new anti-CoV drugs.

Quantum dots (QDs) are the nano (2 to 10 nm ) semiconductor crystals with unique electronic and optical properties used in biomedical sector as they cross the BBB in conjugation with a therapeutic molecule [91] . Specifically high quantum yield, size-tunable light emission, intensive fluorescence, appreciable chemical and photo-stability have revolutionized the concept of nano-based sensing or diagnostics [92] . Giaxia et al.

showed that QDs in conjugation with transferrin (targeting molecule) and Sequinavir could freely cross an in vitro model of BBB with promising anti-viral activity against HIV [93] . In addition, QDs have been utilized either as therapeutics or for in vitro diagnosis of viral pathogens. Much progress has been made in the evaluation of carbon-based nanosystems against viral infection, but their commercialization depends on the safety and superiority over the competing methods [94] .

The use of organic NPs (ONP) over INPs is well studied in biomedical field due to various safety issues [95] . ONP possess many advantages over other nanoparticles platforms, such as self-assembly in physiologically mild conditions, and chemical diversity for accommodating a variety of modalities, sizes, surface functionalization, shapes, and compositions [75] . Multiple forms of ONP are being exploited in nanomedicine but only few are presently being evaluated for their virucidal activity. These include lipid based NP, polymeric NP, and dendrimers.

NP made from lipids is unique class for biomedical applications comprised of outer biodegradable phospholipid bilayer and an inner hydrophilic core designed to hold aqueous therapeutic agents. The flexibility of liposome is to hold both hydrophobic and hydrophilic molecules. A major advantage of liposomal NP is the versatility of the lipid bilayer, which can be functionalized with targeting moieties. Chemical diversity, high loading capacity, and intrinsic bio-degradability are the characteristics beneficial to drug delivery [96] .

The pH-sensitive or thermo sensitive linkers can be used to release the drug payload in response to environmental conditions for prolonged stimulation of immune response.

Modifying surface charge of liposomes can also be used to enhance the bioavailability to explore the negative charge of mucosal membrane and escape form the clearance mechanism of mucosal cilia [97] . Das et al. reported that the bioactive lipids such as Arachidonic acid J o u r n a l P r e -p r o o f and other unsaturated fatty acids can inactivate enveloped viruses including SARS-CoV-2, SARS and MERS to combat COVID-19 [98] . Furthermore, liposomes with bioactive lipids have the great potential for anti-viral therapy.

Polymeric MP and NP (PNP) has shown the exciting features such as flexible properties, viable synthetic protocols, and biocompatibility, making it an interesting candidate for biomedical applications. PNP can be synthesized with the help of polymers such as linear, branched, and 3D networks (i.e. highly branched) of natural or synthetic origin [99] . Various polymers have immensely contributed to accurate understanding of properties such as biocompatibility, bioavailability, immune-compatibility etc. for biomedical sciences.

Poly (lactic-co-glycolic acid) (PLGA) is the well explored polymer approved by FDA due to biocompatibility and biodegradability in the human body [58] . Synthetic hydrophobic polymers are commonly used in the fabrication of MPs with the aim of sustained drug release. Inhalable PLGA, PCL or PLA MPs were successfully fabricated by spray-drying of mixed organic solution. But their uses either for development or for improvement of an antiviral have been investigated only for some pathogenic viruses like influenza, HIV and rabies virus [74] .

As an alternative to synthetic polymers, some natural polymers e.g. sodium alginate [100] and ability to be easily modified into desired shape and sizes [101] . Chitosan can enhance endurance of PNP in mucosal environment and penetration to mucosal tissue, when conjugate with therapeutics [102] . Some other polymers e.g. sodium hyaluronate (HYA) are utilized for pulmonary drug delivery based on their targeting potential in lungs [103] . HYA played a vital role in controlling tumor proliferation and metastasis via targeting CD-44 receptors [104] .

Dendrimers NP are three-dimensional hyperbranched organic compounds, wellorganized nanoscopic molecules, possess low poly-dispersity index, biocompatibility and biodegradability in the field of nanomedicine [105] . This allows the potential utilization of dendrimers NP in various therapies against tumors, bacterial and viral infections. Dendrimers act as extraordinary vehicle for the targeted delivery of drug/ gene/ peptides in biological system with limited utility and application in antiviral therapy [106] . The globular structure J o u r n a l P r e -p r o o f Journal Pre-proof of dendrimers enables NP to accommodate drug molecules in the interior cavity i.e. by physical encapsulation and on surface by covalent conjugation [107] . To date, dendrimers with anti-viral activity in conjugation with therapeutic agents have already been documented against some viruses including influenza virus, Ebola-virus, zika virus, HSV-1, 2 and HIV.

Research on the efficacy of dendrimers as a nanoparticulate system for designing an anti-viral therapy have been introduced by some of the pioneering researches, but their efficiency against is yet to be evaluated [74] .

Hybrid nanosystems are combination of inorganic-organic, inorganic-inorganic, and organic-organic nanoparticulate systems engineered based on specific requirement or use at [110] . In the roles of various beneficiaries, biocompatibility, in vivo biodistribution, biodegradation, and bio-corona formation are some of the important features that continue to shape the current scientific community to this day.

The objectives of the research agenda are to combat COVID-19 through rapid diagnosis, in facilitating ideal care to all the affected persons, to learn from the current outbreak response and be prepared for unpredictable epidemics in future. The research agenda can be divided into five broad areas of research action as summarized in figure 5. [112] . Early studies identified patients with other medical conditions such as diabetes, hypertension and cardiovascular disease had more severe infections, and the disease was more common in men. Very few cases have been reported in children [11] . There is currently limited understanding of severity in different populations and risk groups.

Family cluster studies [113] , case studies, mathematical modeling to determine transmission parameters are being investigated carefully to understand COVID-19 in better way [114] [115] [116] . The further research in the field of epidemiology should be directed to understand the transmission potential, transmission dynamics, identify effective control and mitigation measures.

The knowledge of immunology directly or indirectly aids in the development of interventions and clinical management of COVID -19. The basic information of immunology is to know about the role of innate and adaptive immune response in clearance of pathogen.

As a part of innate immunity body produces inflammatory proteins like interferons (including IL-1β, IL-6, TNF-α, etc.) as first line defense. Adaptive immune response involves B cell activation resulting in antibody production. In addition, T lymphocytes including CD4+ T cell derived cytokines, CD8+ T cell mediated cytotoxicity play important role in clearance of virus. However, adaptive and innate immune responses work together in sequence to combat any viral infection in healthy immune cells. In case of defective immune response or dysfunctional immune, cytokine storm will be triggered and circulates to other organs, leading to lung and multi-organ damage [117] .

Some studies have suggested that SARS-CoV-2 has the capacity to escape innate immune responses but the mechanism remains unclear [117] [118] [119] . Further studies to characterize the host immunity, population immunity, vaccine-induced immunity and mucosal immunity are necessary. To support the research and development, studies regarding the strength, kinetics and the duration of immunity need to be clarified. In addition, detailed investigation of the determinants of healthy versus dysfunctional outcomes is required to combat COVID-19.

Viral therapeutics to fight COVID-19 includes monoclonal antibodies, repurposed drugs or anti-viral drugs in development stage. To deal with the outbreak immediately, the only option is to repurpose the antiviral drugs due to lack of time by evaluating its safety and efficacy. Among the landscape of therapeutics, based on the broad antiviral spectrum, Remdesivir was considered as first priority. Among the repurposed drugs, the investigation of the anti-retroviral medicine (HIV protease inhibitors), lopinavir/ritonavir, either alone or in combination with Interferon β was considered a suitable second option for rapid implementation in clinical trials [120] . However, immunotherapies like convalescent sera or other agents are also considered for the treatment option. There is no evidence at this point that people can't be reinfected with the virus and the development of an antibody response will be protective from secondary infection, according to WHO. Some countries suggested detection of antibodies to COVID -19, could serve as the J o u r n a l P r e -p r o o f basis for an 'immunity passport' or certificate of immunity assuming that they are protected against re-infection. But WHO said that issuing such certificate increases the severity of the disease. HERD immunity would be played an important role to address the devastating COVID-19, which is an indirect protection conferred to the susceptible ones by immune individuals against a specific pathogenic infestation in a given population [112] . It is possible only through vaccination. Vaccine approval may take up to a decade or more to win approval based on their ability to prevent disease in population. Typically, HERD immunity isn't achieved in a short time like year or two and would take several years to confer sufficient ' HERD immunity' to fight COVID-19 [126] . J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f Electroporation results in small pores on the cells to aid the uptake of the nucleic acid vaccine. The cells then start to create the proteins encoded on the DNA plasmid and produce Phase 2

Vaccine consists of doublestranded DNA plasmid that encodes antigens found in SARS-CoV-2. It is intradermally delivered into the arm of patients using proprietary CELLECTRA [136] J o u r n a l P r e -p r o o f 

Three Emerging Coronaviruses in Two Decades: The Story of SARS, MERS, and Now COVID-19

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-A n update on the status

Coronavirus disease 2019: What we know?

Evidence based management guideline for the COVID-19 pandemic -Review article

Clinical management of COVID-19

Therapeutic Management of COVID-19 Patients: A systematic review

Solidarity clinical trial for COVID-19 treatments

Evolutionary trajectory for the emergence of novel coronavirus SARS-CoV-2, Pathogens

The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control

Coronaviruses-drug discovery and therapeutic options

Clinical features of patients infected with 2019 novel coronavirus in

Novel Wuhan (2019-NCoV) coronavirus

Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention

The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike

Features, Evaluation and Treatment Coronavirus (COVID-19)

New Insights of Emerging SARS-CoV-2: Epidemiology, Etiology, Clinical Features

NanoViricides Inc: A New Era in Targeted Anti-Viral Therapeutics

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Cytokine release syndrome in severe COVID-19, Science (80-. )

The pathogenesis and treatment of the 'Cytokine Storm'' in COVID-19

Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirusspecific human monoclonal antibody

Experimental Treatment with J o u r n a l P r e -p r o o f Favipiravir for COVID-19: An Open-Label Control Study, Engineering

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Spotlight of Remdesivir in Comparison with Ribavirin, Favipiravir, Oseltamivir and Umifenovir in Coronavirus Disease 2019 (COVID-19) Pandemic, SSRN Electron

COVID-19: A promising cure for the global panic

Translation: Management of Coronavirus Disease

COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine | FDA

The current understanding and potential therapeutic options to combat COVID-19

Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label nonrandomized clinical trial

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19

COVID-19 presenting as stroke

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19 | Roivant Sciences

Coronavirus as silent killer: recent advancement to pathogenesis, therapeutic strategy and future perspectives

UK researchers launch trial of blood plasma therapy for Covid-19

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Convalescent plasma transfusion for the treatment of COVID-19: Systematic review

On facing the SARS-cov-2 (COVID-19) with combination of nanomaterials and medicine: Possible strategies and first challenges

Targeted Drug Delivery to the Virus-Infected Airway; Complications and Remedies

Pulmonary surfactant inhibits cationic liposome-mediated gene delivery to respiratory epithelial cells in vitro

Inhaled nano-and microparticles for drug delivery

Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead

What It Is and How It Works | Nano

Modeling and Simulations of Polymers: A Roadmap

Unique benefits of nanotechnology to drug delivery and diagnostics

Strategies in the design of nanoparticles for therapeutic applications

Silver Nanoparticles as Potential Antiviral Agents

Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model

Inhalation system for pulmonary aerosol drug delivery in rodents using large porous particles

Development of controlled-release cisplatin dry powders for inhalation against lung cancers

Quercetin solid lipid microparticles: A flavonoid for inhalation lung delivery

Solid lipid budesonide microparticles for controlled release inhalation therapy

Nano-based approach to combat emerging viral (NIPAH virus) infection

Organic and inorganic nanoparticle vaccines for prevention of infectious diseases

Abd El-Hafeiz, Inhibitory effect of silver nanoparticles on bovine herpesvirus-1

OSF Preprints | Formulations for COVID-19 Treatment via Silver Nanoparticles Inhalation Delivery

Silver Nanoparticles with Bronchodilators Through Nebulisation to Treat COVID 19 Patients

Synthesis and evaluation of antiviral activities of novel sonochemical silver nanorods against HIV and HSV viruses

Light-activated nanotube-porphyrin conjugates as effective antiviral agents -J o u r n a l P r e -p r o o f IOPscience

Single-walled carbon nanotubes as candidate recombinant subunit vaccine carrier for immunization of grass carp against grass carp reovirus

Synergistic antiviral effect of curcumin functionalized graphene oxide against respiratory syncytial virus infection

Glycofullerenes inhibit viral infection

Antiviral activity of self-assembled glycodendro[60]fullerene monoadducts

Surface Alterations to Impart Antiviral Properties to Combat COVID-19 Transmission

Drug delivery aspects of carbon nanotubes

A review of ligand tethered surface engineered carbon nanotubes

Enzyme-coated carbon nanotubes as single-molecule biosensors

Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation

Inhibition of SARS-CoV-2 Replication by Acidizing and RNA Lyase-Modified Carbon Nanotubes Combined with Photodynamic Thermal Effect

Quantum dots in imaging, drug delivery and sensor applications

Pharmaceutical and biomedical applications of quantum dots

Theranostic quantum dots for crossing bloodbrain barrier in vitro and providing therapy of HIV-associated encephalopathy

Biological interactions of carbon-based nanomaterials: From coronation to degradation

Is nano safe in foods? Establishing the factors impacting the gastrointestinal fate and toxicity of organic and inorganic food-grade nanoparticles

Liposomes as nanomedical devices

Enhancement of nasal absorption of calcitonin loaded in liposomes

Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?

Molecularly engineered polymer-based systems in drug delivery and regenerative medicine

Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: Microscopic, ultrastructural, and computed-tomographic observations

Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines

Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients Therapeutic Managment of COVID-19 Patients: A systematic review View project

The Rise and Fall of Hyaluronan in Respiratory Diseases

Hyaluronic acid targeting of CD44 for cancer therapy: From receptor biology to nanomedicine

Mechanistic Studies of Viral Entry: An Overview of Dendrimer-Based Microbicides As Entry Inhibitors Against Both HIV and HSV-2 Overlapped Infections

PEGylated dendrimer-entrapped gold nanoparticles with low immunogenicity for targeted gene delivery

Dendrimers in anticancer drug delivery: mechanism of interaction of drug and dendrimers

Poly (vinyl pyrrolidone)-lipid based hybrid nanoparticles for anti viral drug delivery

Nanotechnology for COVID-19: Therapeutics and Vaccine Research

COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Report 2: Estimating the potential total number of novel Coronavirus (2019-nCoV) cases in Wuhan City

Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions n

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

The trinity of COVID-19: immunity, inflammation and intervention

SARS coronavirus and innate immunity

SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes

Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection

World Health Organisation, a Coordinated Global Research Roadmap

The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat

Risk of Developing Posttraumatic Stress Disorder in COVID-19 Survivors : What Should Mental Health Specialists Prepare For ? Risk of Developing Posttraumatic Stress Disorder in COVID-19 Survivors : What Should Mental Health Specialists Prepare For ?

Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China

Herd immunity" will take longer. | BioPharma Dive

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

A Study of a Candidate COVID-19 Vaccine (COV001) -Full Text View -ClinicalTrials.gov

University of Oxford Commences Clinical Trial for Vaccine Candidate (ChAdOx1 nCoV-19) Targeting COVID-19

Update: China approves three COVID-19 vaccines for clinical trials -Xinhua | English.news.cn

CanSinoBIO's Investigational Vaccine Against COVID-19 Approved for Phase 1 Clinical Trial in China-CanSino Biologics Inc

Ad5-nCoV COVID-19 Vaccine -Precision Vaccinations

Number Type of Product-Treatment FDA-Approved Indications Clinical Trials for Other Diseases Developer/Researcher Current Stage of Development Funding Sources Clinical Trials for COVID-19 Anticipated Next Steps Timing

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity J o u r n a l P r e -p r o o f of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older -Full Text View -ClinicalTrials

The advantage of RNA-based vaccine-COVID-19 vaccine: What is the current status of Moderna vaccine and everything you should know about it

The COVID-19 vaccine development landscape

COVID-19 Vaccine and Therapeutic Drugs Tracker

Covid-19 Candidate Vaccines In Clinical Evaluation

Candidate-Vaccines-In-Clinical-Evaluation

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 -Full Text View -ClinicalTrials.gov

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19) -Full Text View -ClinicalTrials.gov

Novavax to commence human trial for Covid-19 vaccine

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant -Full Text View -ClinicalTrials.gov

Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults -Full Text View -ClinicalTrials.gov

and Safety of Covid-19 Synthetic Minigene VaccineImmunity -Full Text View -ClinicalTrials.gov

Cytotoxicity and antiviral activity of electrochemical -synthesized silver nanoparticles against poliovirus

Delivery of VP1 siRNA to inhibit the EV71 virus using functionalized silver nanoparticles through ROS-mediated signaling pathways

Glutathione-Capped Ag2S Nanoclusters Inhibit Coronavirus Proliferation through Blockage of Viral RNA Synthesis and Budding

Amantadine Surface-Modified Silver Nanorods Improves Immunotherapy of HIV Vaccine Against HIV-Infected Cells

Antiviral and immunomodulatory activity of silver nanoparticles in experimental rsv infection

Evaluation of G2 Citric Acid-Based Dendrimer as an Adjuvant in Veterinary Rabies Vaccine

Nanostructures based on ammonium-terminated amphiphilic Janus dendrimers as camptothecin carriers with antiviral activity

An RNA nanoparticle Vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model

Antiviral activity of self-assembled glycodendro[60]fullerene monoadducts

A multi-functional gold/iron-oxide nanoparticle-CNT hybrid nanomaterial as virus DNA sensing platform

Highly monodispersed J o u r n a l P r e -p r o o f gold nanoparticles synthesis and inhibition of herpes simplex virus infections

Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy

Novel dendritic structure of alginate hybrid nanoparticles for effective anti-viral drug delivery

Glycyrrhizic-Acid-Based Carbon Dots with High Antiviral Activity by Multisite Inhibition Mechanisms

We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work.[OR]We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.

Nanoparticle Virus Mechanism of action Inference References

Gly-CDs can inhibit PRRSV invasion and replication, stimulate antiviral innate immune responses, and inhibit the accumulation of intracellular reactive oxygen species (ROS) caused by PRRSV infection.Gly-CDs possess extraordinary antiviral activity with multisite inhibition mechanisms, providing a promising candidate [159] J o u r n a l P r e -p r o o f